Lyell Immunopharma (LYEL) Other Non-Current Liabilities (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Other Non-Current Liabilities data on file, last reported at $527000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 83.22% year-over-year to $527000.0; the trailing twelve-month figure through Mar 2026 stood at $527000.0 (down 83.22% YoY), and the FY2025 full-year result was $517000.0, down 84.11% from the prior year.
• Other Non-Current Liabilities rose to $527000.0 in Q1 2026, from $517000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $5.5 million in Q2 2025 to a low of $517000.0 in Q4 2025.
• A 5-year average of $3.5 million and a median of $3.7 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities jumped 382.22% in 2022 and plunged 84.11% in 2025, its largest moves.
• Tracing LYEL's Other Non-Current Liabilities over 5 years: stood at $4.1 million in 2022, then retreated by 10.92% to $3.7 million in 2023, then retreated by 11.22% to $3.3 million in 2024, then sank by 84.11% to $517000.0 in 2025, then advanced by 1.93% to $527000.0 in 2026.
• Business Quant data shows LYEL's Other Non-Current Liabilities at $527000.0 in Q1 2026, $517000.0 in Q4 2025, and $2.7 million in Q3 2025.